Medication info
VIVACO Tablets 10 mg (Rosuvastatin Calcium)

VIVACO Tablets 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
HK inno.N corporation
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201400434 · Approved 2014.01.29 · Insurance code 640006740

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Ingredients

Importer
HK inno.N corporation

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • primary dyslipidemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct to diet for the treatment of primary hypercholesterolemia and mixed dyslipidemia, particularly when diet and exercise alone do not achieve adequate control. It also enhances the treatment effect in patients with homozygous familial hypercholesterolemia when used in combination with other lipid-lowering therapies. It helps lower total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is used to reduce cholesterol levels in children and adolescents aged 10 years and older with heterozygous familial hypercholesterolemia when diet alone is insufficient for improvement. It also acts as an adjunct to diet in patients with primary dysbetalipoproteinemia, and helps to reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk patients with cardiovascular disease risk factors. This medication effectively improves cholesterol management and reduces the risk of cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, patients with an allergy to any component of this medication, those with severely impaired liver function, those with muscle diseases, those taking certain medications, those with severe renal impairment, pregnant or nursing women, and women of childbearing age who do not use adequate contraceptive measures should not take this medication. This medication should be used with caution in patients at high risk of muscle diseases. If symptoms of muscle pain or weakness occur, consultation with a physician should be sought immediately, and regular blood tests are necessary to check for muscle damage during treatment. Since this medication can affect liver function, patients with a history of liver disease should consult their physician before taking it and should regularly monitor liver function during use. Patients who consume excessive alcohol or have hypothyroidism should be cautious when taking this medication, and it is important to treat these underlying conditions first. This medication can interact with other drugs, so if patients are currently taking other medications, they must inform their physician. In particular, the risk of muscle damage may increase when taken with certain antivirals, immunosuppressants, antibiotics, and fibrate drugs. Women who are pregnant or planning to become pregnant should consult their physician before taking this medication and use appropriate contraceptive methods. Nursing women should also avoid taking this medication. In case of overdose, there is no specific antidote, so patients should visit a medical institution immediately for treatment based on symptoms, and liver function and muscle damage should be monitored. This medication can rarely cause serious skin reactions or liver damage, so if symptoms such as skin rash or jaundice occur, the medication should be stopped immediately, and medical attention should be sought. Dizziness or headache may occur, so caution is advised when driving or operating machinery. Finally, this medication can also be used in children and adolescents, but it should be taken carefully as it can affect growth and development of secondary sexual characteristics, following the instructions of healthcare professionals.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, morbiliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.